Shield Therapeutics plc (LON:STX – Get Free Report)’s stock price reached a new 52-week low during trading on Friday . The stock traded as low as GBX 3.80 and last traded at GBX 3.95, with a volume of 25964117 shares trading hands. The stock had previously closed at GBX 4.40.
Shield Therapeutics Stock Down 10.2%
The company has a quick ratio of 2.16, a current ratio of 0.90 and a debt-to-equity ratio of -199.87. The stock has a market cap of £42.25 million, a PE ratio of -1.98 and a beta of 1.76. The firm has a fifty day moving average of GBX 6.06 and a 200 day moving average of GBX 8.
About Shield Therapeutics
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.
See Also
- Five stocks we like better than Shield Therapeutics
- Popular’s Earnings Beat Shows Why This Bank Stock Keeps Climbing
- ABB’s Rotork Deal Could Put These Flow Control Stocks Back in Focus
- GE HealthCare Stock Climbs on Vital Diagnostics Demand
- Lost in Space: Why Aerospace Valuations Are Plummeting Right Now
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
